Glaukos
GKOS
Market cap $5.58B

97.60 USD

+0.00

0.00%

At close Jun 13, 4:00 PM EDT

After hours

97.60

+0.00

0.00%

1 day

0.00%

5 days

3.76%

1 month

5.67%

3 months

1.04%

6 months

-29.75%

Year to date

-34.79%

1 year

-14.11%

5 years

145.23%

10 years

212.62%

About: Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Employees: 995

Healthcare Medical Devices

0

Funds holding %

of 7,296 funds

0

Analysts bullish %

of 8 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

2% more repeat investments, than reductions

Existing positions increased: 115 | Existing positions reduced: 113

5% less first-time investments, than exits

New positions opened: 54 | Existing positions closed: 57

2% less funds holding

Funds holding: 321 [Q4 2024] → 314 (-7) [Q1 2025]

2.99% less ownership

Funds ownership: 103.62% [Q4 2024] → 100.63% (-2.99%) [Q1 2025]

33% less funds holding in top 10

Funds holding in top 10: 6 [Q4 2024] → 4 (-2) [Q1 2025]

34% less capital invested

Capital invested by funds: $8.57B [Q4 2024] → $5.65B (-$2.92B) [Q1 2025]

64% less call options, than puts

Call options by funds: $27.9M | Put options by funds: $77.9M

See Fund Rankings

Research analyst outlook

8 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$72

26%

downside

Avg. target

$122

25%

upside

High target

$175

79%

upside

8 analyst ratings

6 positive

75%

1 neutral

13%

1 negative

13%

Morgan Stanley Patrick Wood	26%downside $72	Underweight Maintained	6 May 2025
Stephens & Co. Mason Carrico	18%upside $115	Overweight Maintained	2 May 2025
Stifel Thomas Stephan	18%upside $115	Buy Maintained	1 May 2025
Truist Securities Richard Newitter	38%upside $135	Buy Reiterated	1 May 2025
Wells Fargo Larry Biegelsen	12%downside $86	Equal-Weight Downgraded	1 May 2025

See Analyst Rankings

Financial journalist opinion

Zacks Investment Research

Can Glaukos (GKOS) Climb 34.4% to Reach the Level Wall Street Analysts Expect?

The mean of analysts' price targets for Glaukos (GKOS) points to a 34.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Can Glaukos (GKOS) Climb 34.4% to Reach the Level Wall Street Analysts Expect?

Zacks Investment Research

Here's Why You Should Retain Glaukos Stock in Your Portfolio

GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism.

Here's Why You Should Retain Glaukos Stock in Your Portfolio

Glaukos Announces Participation in Upcoming Investor Conferences

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the following upcoming investor conferences: Stifel 2025 Virtual Ophthalmology Forum on Tuesday, May 27, 2025, at 12:30 p.m. ET William Blair 45th Annual Growth Stock Conference on Tuesday, June 3, 2025.

Glaukos Announces Participation in Upcoming Investor Conferences

Zacks Investment Research

Glaukos (GKOS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Glaukos (GKOS) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Glaukos (GKOS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks Investment Research

GKOS Stock Falls Despite Q1 Earnings & Revenue Beat, Margins Decline

Glaukos' first-quarter results showcase a strong uptick in revenues. However, continued operating loss remains a cause of concern.

GKOS Stock Falls Despite Q1 Earnings & Revenue Beat, Margins Decline

Glaukos Corporation (GKOS) Q1 2025 Earnings Call Transcript

Glaukos Corporation (NYSE:GKOS ) Q1 2025 Earnings Conference Call April 30, 2025 4:30 PM ET Company Participants Chris Lewis - Vice President of Investor Relations and Corporate Affairs Tom Burns - Chairman and CEO Joe Gilliam - President and COO Alex Thurman - CFO Conference Call Participants Tom Stephan - Stifel Ryan Zimmerman - BTIG Larry Biegelsen - Wells Fargo Allen Gong - J.P. Morgan David Saxon - Needham Adam Maeder - Piper Sandler Joanne Wuensch - Citibank Margaret Andrew - William Blair Richard Newitter - Truist Securities Michael Sarcone - Jefferies Anthony Petrone - Mizzou Group Danielle Antalffy - UBS Patrick Wood - Morgan Stanley Operator Welcome to Glaukos Corporation First Quarter 2025 Financial Results Conference Call.

Glaukos Corporation (GKOS) Q1 2025 Earnings Call Transcript

Zacks Investment Research

Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates

Glaukos (GKOS) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.70 per share a year ago.

Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates

Glaukos Announces First Quarter 2025 Financial Results

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the first quarter ended March 31, 2025. Key highlights include: Record net sales of $106.7 million in Q1 2025 increased 25% year-over-year on a reported basis and 26% year-over-year on a constant currency basis. Glaucoma record net.

Glaukos Announces First Quarter 2025 Financial Results

Baron Health Care Fund Q1 2025 Top Contributors And Detractors

Boston Scientific's shares rose due to strong market growth, innovative products like pulsed field ablation, and disciplined cost management, driving double-digit EPS growth. Vertex Pharmaceuticals saw increased investor confidence in its cystic fibrosis franchise and evolving pipeline, including promising non-opioid pain treatments and kidney disease drugs. UnitedHealth Group's shares gained as 2024 headwinds subsided, Medicare Advantage rates improved, and higher-margin Optum segments grew, insulating it from tariff impacts.

Baron Health Care Fund Q1 2025 Top Contributors And Detractors

Zacks Investment Research

Glaukos (GKOS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Glaukos (GKOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Glaukos (GKOS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

See News Rankings

Charts implemented using Lightweight Charts™